445-449
Clinical Trial
Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil
Dong-Hyun Choi, Wan-Gyun Shin and Jun-Shik Choi
451-456
Special Article
A nurse-led intervention for identification of drug-related problems
Monica Bergqvist, Johanna Ulfvarson, Eva Andersen Karlsson and Christer von Bahr
457-463
Pharmacodynamics
The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects
John M. Kovarik, Michael Lu, Gilles-Jacques Riviere, Irene Barbet and Steve Maton, et al.
465-475
Pharmacogenetics
The
CYP2D6
gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements
Andrea Gaedigk and Christa Coetsee
477-482
Pharmacogenetics
Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients
Arzu Gunes, Marja-Liisa Dahl, Edoardo Spina and Maria Gabriella Scordo
483-487
Pharmacogenetics
Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele
M. Hermann, M. Hendset, K. Fosaas, M. Hjerpset and H. Refsum
489-495
Pharmacokinetics and Disposition
Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients
Anna Ferrari, Diego Pinetti, Alfio Bertolini, Ciro Coccia and Emilio Sternieri
497-502
Pharmacokinetics and Disposition
Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?
Kristin Moksnes, Olav M. Fredheim, Pål Klepstad, Stein Kaasa and Anders Angelsen, et al.
503-509
Pharmacokinetics and Disposition
Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers
Takenori Niioka, Masatomo Miura, Tsukasa Uno, Norio Yasui-Furukori and Makoto Hayakari, et al.
511-519
Pharmacokinetics and Disposition
Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo
Marjo J. Karjalainen, Pertti J. Neuvonen and Janne T. Backman
521-529
Pharmacokinetics and Disposition
Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops
Khaled Abduljalil, Michael Diestelhorst, Oxana Doroshyenko, Anja Lux and Andre Steinfeld, et al.
531-538
Pharmacoepidemiology and Prescription
Open AccessThe association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports
Hieronymus J. Derijks, Ronald H. B. Meyboom, Eibert R. Heerdink, Fred H. P. De Koning and Rob Janknegt, et al.
539-543
Pharmacoepidemiology and Prescription
Open AccessTen years after the Dutch public health campaign on folic acid: the continuing challenge
Hermien E. K. de Walle and Lolkje T. W. de Jong-van den Berg
545-552
Pharmacoepidemiology and Prescription
Open AccessPredictors of orphan drug approval in the European Union
Harald E. Heemstra, Remco L. de Vrueh, Sonja van Weely, Hans A. Büller and Hubert G. M. Leufkens
553-554
Letter to the Editors
Detection of the pharmaceutical agent glaucine as a recreational drug
Paul I. Dargan, Jenny Button, Leonard Hawkins, John R. H. Archer and Hanna Ovaska, et al.